Cantargia AB Q1 2025 Earnings Call Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: Luisa Morgado - Van Lanschot Kempen - Analyst : Hi, Tim. Thank you for taking my questions. Maybe to start out with can 10, I was wondering, since you're now starting the cohort and healthy volunteers and the one with iniasis continues with recruitments, I was wondering when will you share more data if this will just happen throughout each one of this year. And then also for can 10, in terms of the pilot study and atopic dermatitis, could you provide any more details here in terms of trial design, timelines, duration, that sort of thing?

Question: Luisa Morgado - Van Lanschot Kempen - Analyst : Thank you. Yes, very clear. Thank you. And nice to meet you, Martin. Maybe just one final question from my side then. In terms, so you mentioned the regulatory interactions that you will, that you are planning for this year for Na map. Could you just elaborate in terms of what do you expect to gather in terms of conclusions here? And this is not only relative to, just a diagnostic test, right? This is also just for the trial design of C.

Question: Luisa Morgado - Van Lanschot Kempen - Analyst : Okay, thank you so much. That's all from my side.

Question: Richard Ramanius - Redeye - Analyst : Good afternoon. I had some questions relating to the clinical study. It's still study of 10. So I guess that's for Morton. Did you say something more about the design of the study, what line patients we use to factory. Or I say Patients haven't undergone treatment before. And, you mentioned in your presentation that you would use the high score 75. So, what are, is it something about your expectations in this, since I know so so I came up from moon, like they made a lot about there, I think it was high score 75 if I remember correctly, which was superior and they, their fi to study. So what relative performance would you expect? And also it's a I may ask you straight away. There have been issues with these two studies not translating perfectly into phase 3, in HS and I think in psoriasis as well. Are you taking that into account in the design of the phase 2 study?

Question: Richard Ramanius - Redeye - Analyst : Yeah, what line of the patient treatment name or if they're reflect it.

Question: Richard Ramanius - Redeye - Analyst : Yeah, right.

Question: Richard Ramanius - Redeye - Analyst : So, let's say if you achieve these results, how would that translate into for replacement. I guess it would be difficult to get it in the second line in that case, or if you get a really great score, wouldn't that, would that be possible?

Question: Richard Ramanius - Redeye - Analyst : Okay, interesting. Let's see, I had some More questions pertaining To Nainoleab. What phase two activities remain. Before you can, or let's say pre pre preparatory activities remain before you can start a phase two study. You mentioned you had produced enough substance or you doing long term toxicology studies or other activities.

Question: Richard Ramanius - Redeye - Analyst : No, sorry, I mean, no, you're right, it was, this was about. Yeah, this will work on 10. No, I'm my mistake, but you give the right answer. Now my question in the no map was. I misplaced my notes. My question about another number was, when do you expect the results from the leukemia study?

Question: Richard Ramanius - Redeye - Analyst : Okay, thanks. That's All my questions.

Question: Sten Westerberg - Analysguiden - Analyst : Okay. Congratulations to a very productive worker. Two questions on 0. 1st, if you can break up the expansion of the phase one trial a little bit more if originally estimated that enrolling 80 patients and now. En rolling up to 116, it's a quite a big expansion for phase one study in my mind. Is this entirely related to the SAD, group, or have you made changes in the other groups as well? That's my first one. And also on the pharmacokinetics of the molecule, will you have to give a loading dose of can 11 in phase two, or will you directly move into a 4 week dosing schedule? These are my two questions.

Question: Sten Westerberg - Analysguiden - Analyst : Yes, it would be interesting if you will need a loading dose of Canan in the future studies or if you can move directly into the 4 week dosing schedule.

Question: Sten Westerberg - Analysguiden - Analyst : Right, one loading dose.

Question: Sten Westerberg - Analysguiden - Analyst : Okay, understood. Yes. So I understand there will be a loading phase in the study.

Question: Sten Westerberg - Analysguiden - Analyst : In the ADC field where there appears to be lots of activities from all parties involved in oncology drug development, will you, can you provide us with any more future plans or directions of your own, the clinical programs? Will you be able to come up with a CD? Anytime soon, or which are your plans in this interesting field? REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies. MAY 13, 2025 / 1:00PM, CANTA.ST - Q1 2025 Cantargia AB Earnings Call

Question: Sten Westerberg - Analysguiden - Analyst : Okay. Thank you. That concludes my questions.